Exposure and response prevention versus stress management training for adults and adolescents with obsessive compulsive disorder: A randomized clinical trial
- PMID: 38103359
- PMCID: PMC11639395
- DOI: 10.1016/j.brat.2023.104458
Exposure and response prevention versus stress management training for adults and adolescents with obsessive compulsive disorder: A randomized clinical trial
Abstract
Objective: Though exposure and response prevention (ERP) is a well-proven treatment for OCD across the lifespan, prior RCTs have not studied adolescent and adult patients with the same ERP protocol relative to an active comparator that controls for non-specific effects of treatment. This approach assesses differences in the effect of OCD-specific exposures in affected adolescents and adults and in response to ERP compared to a stress-management control therapy (SMT).
Methods: This assessor-blinded, parallel, 2-arm, randomized, ambulatory clinical superiority trial randomized adolescents (aged 12-18) and adults (24-46) with OCD (N = 126) to 12 weekly sessions of ERP or SMT. OCD severity was measured before, during and after treatment using the child or adult version of the Yale-Brown Obsessive Compulsive Scale (C/Y-BOCS), depending on participant age. We predicted that ERP would produce greater improvement in OCD symptoms than SMT and that there would be no significant post-treatment differences across age groups.
Results: ERP (n = 63) produced significantly greater improvements on C/Y-BOCS scores at post-treatment than SMT (n = 63) (Effect size = -0.72, CI = -0.52 to -0.91, p < .001). ERP also produced more treatment responders (ERP = 86%, SMT = 32%; χ2 = 46.37, p < .001) and remitters than SMT (ERP = 39%, SMT = 7%; χ2 = 16.14, p < .001). Finally, there were no statistically significant post-treatment differences in C/Y-BOCS scores between adolescents and adults assigned to ERP.
Conclusion: A single ERP protocol is superior to SMT in treating both adolescents and adults with OCD. OCD-specific therapy is necessary across the lifespan for optimal outcomes in this highly disabling disorder, though non-specific treatments like SMT are still all-too-commonly provided.
Trial registration: ClinicalTrials.gov NCT02437773.
Keywords: Adolescents; Adults; Exposure and response prevention; Obsessive compulsive disorder; Stress management.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest Declarations of interest: none.
Figures
Similar articles
-
Resting-State Connectivity and Response to Psychotherapy Treatment in Adolescents and Adults With OCD: A Randomized Clinical Trial.Am J Psychiatry. 2023 Jan 1;180(1):89-99. doi: 10.1176/appi.ajp.21111173. Epub 2022 Dec 7. Am J Psychiatry. 2023. PMID: 36475374 Free PMC article. Clinical Trial.
-
Group Acceptance and Commitment Therapy versus Cognitive Behavioral Therapy/Exposure Response Prevention for Obsessive Compulsive Disorder: A Block Randomized Controlled Trial.Psychother Psychosom. 2025;94(3):135-146. doi: 10.1159/000544070. Epub 2025 Feb 21. Psychother Psychosom. 2025. PMID: 39987908 Clinical Trial.
-
Exposure Therapy in Mixed Reality for Obsessive-Compulsive Disorder: A Randomized Clinical Trial.JAMA Netw Open. 2025 May 1;8(5):e2511488. doi: 10.1001/jamanetworkopen.2025.11488. JAMA Netw Open. 2025. PMID: 40392553 Free PMC article. Clinical Trial.
-
D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.Drug Des Devel Ther. 2015 Apr 21;9:2101-17. doi: 10.2147/DDDT.S68994. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25960632 Free PMC article. Review.
-
Family-Based Psychological Treatment for Obsessive Compulsive Disorder in Children and Adolescents: A Meta-analysis and Systematic Review.Clin Child Fam Psychol Rev. 2019 Dec;22(4):478-501. doi: 10.1007/s10567-019-00296-y. Clin Child Fam Psychol Rev. 2019. PMID: 31240488
Cited by
-
Treatment expectancy and credibility as predictors of concentrated exposure treatment outcomes in patients with difficult-to-treat obsessive-compulsive disorder.BMC Psychiatry. 2025 Mar 25;25(1):275. doi: 10.1186/s12888-025-06737-z. BMC Psychiatry. 2025. PMID: 40133857 Free PMC article. Clinical Trial.
References
-
- Abramowitz JS (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review. Journal of Consulting and Clinical Psychology, 65(1), 44–52. - PubMed
-
- Abramowitz JS, Deacon BJ, Olatunji BO, Wheaton MG, Berman NC, Losardo D, et al. (2010). Assessment of obsessive-compulsive symptom dimensions: Development and evaluation of the dimensional obsessive-compulsive scale. Psychological Assessment, 22(1), 180. - PubMed
-
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
-
- Anholt GE, Aderka IM, Van Balkom AJ, Smit JH, Hermesh H, De Haan E, et al. (2011). The impact of depression on the treatment of obsessive–compulsive disorder: Results from a 5-year follow-up. Journal of Affective Disorders, 135(1–3), 201–207. - PubMed
-
- Bernstein IH, Rush AJ, Suppes T, Trivedi MH, Woo A, Kyutoku Y, et al. (2009). A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. International Journal of Methods in Psychiatric Research, 18(2), 138–146. - PMC - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical